Fulcrum Therapeutics (FULC) Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Current Assets data on file, last reported at $338.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $338.7 million, up 45.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $338.7 million (up 45.63% YoY), and the FY2025 annual result was $357.5 million, up 43.04% from the prior year.
• Current Assets eased to $338.7 million in Q1 2026 per FULC's latest filing, from $357.5 million in the prior quarter.
• Over five years, Current Assets peaked at $357.5 million in Q4 2025 and troughed at $174.2 million in Q2 2022.
• A 5-year average of $251.2 million and a median of $242.2 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets jumped 62.38% in 2023, then retreated 28.03% in 2024.
• A 5-year view of Current Assets shows it stood at $207.5 million in 2022, then advanced by 16.71% to $242.2 million in 2023, then increased by 3.19% to $249.9 million in 2024, then jumped by 43.04% to $357.5 million in 2025, then retreated by 5.26% to $338.7 million in 2026.
• Business Quant data shows FULC's Current Assets at $338.7 million in Q1 2026, $357.5 million in Q4 2025, and $205.9 million in Q3 2025.